Meeting
2020 ASCO Virtual Scientific Program
HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.
Presenter
John Bartlett, PhD
Ontario Institute for Cancer Research
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00003678
Citation
J Clin Oncol 38: 2020 (suppl; abstr 522)
DOI
10.1200/JCO.2020.38.15_suppl.522
Abstract #
522
Poster Bd #
14
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Effect of low-dose tamoxifen on IGF-I/IGFBP-3 and estradiol/SHBG ratio and their prognostic/predictive effect in DCIS/LCIS/ADH.
Speaker: Andrea De Censi, MD
Videos & Slides
2024 ASCO Annual Meeting
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
Speaker: Erin Frances Cobain, MD
Videos & Slides
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
Speaker: Melissa Lynne Johnson, MD